These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35896612)

  • 1. Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma.
    Zhang H; Liu M; Yang Z; Du G; Yu B; Gui Y; Cao L; Li X; Tan B
    Sci Rep; 2022 Jul; 12(1):12785. PubMed ID: 35896612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
    Zhang H; Liu M; Du G; Yu B; Ma X; Gui Y; Cao L; Li X; Tan B
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1597-1612. PubMed ID: 35296921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. m
    Xu F; Huang X; Li Y; Chen Y; Lin L
    Mol Ther Nucleic Acids; 2021 Jun; 24():780-791. PubMed ID: 33996259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
    Sun D; Zhang C
    Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
    Shen Y; Wang S; Wu Y
    Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
    Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
    Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
    Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
    Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
    Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
    Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
    Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
    Front Genet; 2022; 13():838624. PubMed ID: 35928454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
    Ren J; Wang A; Liu J; Yuan Q
    Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
    Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
    Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
    Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
    Front Genet; 2022; 13():862741. PubMed ID: 35368663
    [No Abstract]   [Full Text] [Related]  

  • 15. Mitochondria-related lncRNAs: predicting prognosis, tumor microenvironment and treatment response in lung adenocarcinoma.
    Zhou Q; Xiong J; Gao Y; Yi R; Xu Y; Chen Q; Wang L; Chen Y
    Funct Integr Genomics; 2023 Oct; 23(4):323. PubMed ID: 37864709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
    Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
    Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis for Predicting Prognoses and Immune Responses of m6A-Related lncRNAs in Women with Lung Adenocarcinoma.
    Wu S; Tu Q; Yuan H; Wu Z; Yang Y; Chen C; Huang C
    Biochem Genet; 2024 Aug; 62(4):2702-2720. PubMed ID: 37999876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.
    Fan T; Zhu M; Muhammad S; Xiao C; Li S; Tian H; Liu Y; Xue L; Zheng B; Li C; He J
    Respir Res; 2023 May; 24(1):122. PubMed ID: 37131252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.